Loading...

LivaNova PLC
NASDAQ:LIVN

Watchlist Manager
LivaNova PLC Logo
LivaNova PLC
NASDAQ:LIVN
Watchlist
Price: 54.24 USD -0.88% Market Closed
Updated: Dec 10, 2022

Intrinsic Value

The intrinsic value of one LIVN stock under the Base Case scenario is 72.44 USD. Compared to the current market price of 54.24 USD, LivaNova PLC is Undervalued by 25%.

The Intrinsic Value is calculated as the average of the two valuation methods:

LIVN Intrinsic Value
Base Case
72.44 USD
Undervaluation 25%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Fundamental Analysis

LIVN Profitability Score
Profitability Due Diligence

LivaNova PLC's profitability score is 37/100. The higher the profitability score, the more profitable the company is.

Negative 3-Year Average ROE
Negative Net Income
Negative 3-Year Average ROIC
Positive Free Cash Flow
37/100
Profitability
Score

LivaNova PLC's profitability score is 37/100. The higher the profitability score, the more profitable the company is.

LIVN Solvency Score
Solvency Due Diligence

LivaNova PLC's solvency score is 47/100. The higher the solvency score, the more solvent the company is.

Average Interest Coverage
Low Altman Z-Score
Positive Net Debt
Long-Term Liabilities
47/100
Solvency
Score

LivaNova PLC's solvency score is 47/100. The higher the solvency score, the more solvent the company is.

Financials
Efficiency
71%
Gross Margin
7%
Operating Margin
-9%
Net Margin
6%
FCF Margin
-8%
ROE
4%
ROIC
Other

LIVN Capital Structure
LivaNova PLC

Market Capitalization 2.9B USD
Total Debt 518M USD
Minority Interest 0 USD
Preferred Equity 0 USD
Cash and Equivalents 231M USD
Short-Term Investments 0 USD
Enterprise Value 3.2B USD

Wall St
Price Targets

LIVN Price Targets Summary
LivaNova PLC

Wall Street analysts forecast LIVN stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for LIVN is 73.78 USD with a low forecast of 60.6 USD and a high forecast of 88.2 USD.

Lowest
Price Target
60.6 USD
12% Upside
Average
Price Target
73.78 USD
36% Upside
Highest
Price Target
88.2 USD
63% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

LIVN Competitors
LivaNova PLC

LIVN Suppliers & Customers
LivaNova PLC

LivaNova PLC has 2 key suppliers from 1 countries and 1 industries. The majority of these suppliers are located in the United States of America, with the largest number of suppliers in the Media industry.

Suppliers Map
There is no information about
LivaNova PLC
key suppliers

Ownership

LIVN Insider Trading
Buy and sell transactions by insiders

LivaNova PLC insiders have only sold shares in the past 12 months.

During the last 12 months LivaNova PLC insiders have not bought any shares, and sold 783k USD worth of shares. The last transaction was made on Dec 10, 2022 by Moore Daniel Jeffrey (Director), who sold 83.4k USD worth of LIVN shares.

Sold
0-3
months
0 USD
0
3-6
months
0 USD
0
6-9
months
310k USD
2
9-12
months
473k USD
2
Bought
0-3
months
No Insider Transactions
0
0 USD
3-6
months
No Insider Transactions
0
0 USD
6-9
months
0
0 USD
9-12
months
0
0 USD
Cumulative Transactions Amount
Period Sold Bought Net
3 Months
N/A
N/A
N/A
6 Months
N/A
N/A
N/A
9 Months
310k USD
N/A
-310.3k
12 Months
783k USD
N/A
-783.1k
Purchases
4
Sales
105
Why is insider trading important?

Shareholder Return

LIVN Price
LivaNova PLC

1M 1M
+7%
6M 6M
-18%
1Y 1Y
-34%
3Y 3Y
-32%
5Y 5Y
-34%
Annual Price Range
54.24
52w Low
43.88
52w High
87.8
Price Metrics
Average Annual Return -5.19%
Standard Deviation of Annual Returns 14.23%
Max Drawdown -74%
Shares Statistics
Market Capitalization 2.9B USD
Shares Outstanding 53 522 700
Percentage of Shares Shorted 3.99%

Company Profile

LivaNova PLC

Country

United Kingdom

Industry

Health Care

Market Cap

2.9B USD

Dividend Yield

0%

Description

LivaNova Plc is a global medical technology company, which engages in the development and delivery of therapeutic solutions for the benefit of patients, healthcare professionals, and healthcare systems. The firm is focused on the development and delivery of therapeutic solutions for the benefit of patients, healthcare professionals and healthcare systems throughout the world. The firm operates through two segments: Cardiac Surgery and Neuromodulation. Its Cardiac Surgery Business Franchise (CS) is engaged in the development, production and sale of cardiac surgery products, including oxygenators, heart-lung machines, perfusion tubing systems, cannulae and other accessories used for extracorporeal circulation, systems for autologous blood transfusion and blood washing. Its Neuromodulation Business Franchise designs develops and markets neuromodulation-based medical devices for the treatment of epilepsy and difficult-to-treat depression (DTD) and obstructive sleep apnea.

Contact

London
20 Eastbourne Terrace
+442033250662.0
http://www.livanova.com/home.action

IPO

2015-10-19

Employees

3 000

Officers

CEO & Director
Mr. Damien McDonald
Chief Financial Officer
Mr. Alex Shvartsburg
Chief HR Officer
Ms. Trui Hebbelinck
Sr. VP, Special Advisor & Exec. Officer
Ms. Keyna Pidcock Skeffington
Pres of Cardiopulmonary Bus. Unit
Mr. Marco Dolci
Sr. Director of Investor Relations
Lindsey Little
Show More
Sr. VP, Chief Legal Officer and Company Sec.
Mr. Michael Hutchinson
VP of Corp. Communications
Deanna Wilke
Sr. VP of Corp. Devel.
Mr. Matthew Joseph Dodds III
Sr. VP & Head of Product Devel. - Neuromodulation
Dr. Bryan D. Olin Ph.D.
Show Less

See Also

Similar Stocks
What is the Intrinsic Value of one LIVN stock?

The intrinsic value of one LIVN stock under the Base Case scenario is 72.44 USD.

Is LIVN stock undervalued or overvalued?

Compared to the current market price of 54.24 USD, LivaNova PLC is Undervalued by 25%.